On March 27, 2026, Huadong Medicine Co.,Ltd. announced the approval of a new drug. According to the announcement, an injectable recombinant botulinum toxin type A (R&D code: YY001, brand name: Ruituoxin®), independently developed by its investee company Chongqing Yuyan Pharmaceutical Co., Ltd. with global intellectual property rights, has received marketing approval from the National Medical Products Administration (NMPA). It is indicated for the temporary improvement of moderate to severe glabellar lines in adults aged 65 and younger caused by corrugator and/or procerus muscle activity. Ruituoxin® shares consistent biological function and pharmacological effects with natural botulinum toxin and offers advantages such as high purity, favorable safety, and scalable production. Huadong Medicine holds exclusive commercialization rights and related priority rights for the product's medical aesthetic indications in mainland China, Hong Kong SAR, and Macau SAR. The company also holds a 4.2787% stake in Chongqing Yuyan Pharmaceutical through its wholly-owned subsidiary. The successful approval of Ruituoxin® not only reflects Yuyan Pharmaceutical's R&D capabilities but also marks another significant achievement for Huadong Medicine as a key strategic shareholder in its high-end medical aesthetics portfolio.
The approval of Ruituoxin® is based on a completed Phase III clinical trial in China, which was a multicenter, randomized, double-blind, placebo and active-controlled study evaluating its efficacy and safety for treating moderate to severe glabellar lines. The results demonstrated that its efficacy, safety, and immunogenicity met the predefined clinical endpoints, showing superior performance compared to the control. While botulinum toxin type A has a clear mechanism and broad applications, its industry development has long been constrained by two major bottlenecks: reliance on pathogenic Clostridium botulinum, posing inherent biosafety risks, and low active protein purity in most products, affecting efficacy and safety. As the world's first recombinant botulinum toxin type A, Ruituoxin® innovates the production process, eliminating the biosafety risks associated with traditional bacterial sources. Its advanced manufacturing ensures high purity, high specific activity, and low immunogenicity without altering protein activity. In treating glabellar lines, YY001 demonstrated robust efficacy and a favorable safety profile, showing significant improvement over the vehicle and superior composite response rates at week 4 compared to onabotulinumtoxinA within the statistical framework, supporting its potential as a promising new treatment option.
Ruituoxin® enters a highly promising botulinum toxin market. The Chinese market is not only large but also exhibits strong growth momentum. According to Frost & Sullivan data, the market size grew from RMB 1.9 billion in 2017 to RMB 4.6 billion in 2021, with a compound annual growth rate of 25.6%, and is projected to reach RMB 39 billion by 2030. Leveraging its strong presence and channel resources in the domestic high-end medical aesthetics market, Huadong Medicine will fully integrate the promotional capabilities of its pharmaceutical division in public institution aesthetics and enhance synergy with its commercial system to systematically advance Ruituoxin®'s market access, clinical promotion, and brand building, aiming to maximize its market value and solidify the company's leading position in global medical aesthetics innovation.
Huadong Medicine has comprehensively established its strategic presence in medical aesthetics, successfully building a dual-driven product matrix covering "injectables + energy-based devices" that spans all core non-surgical aesthetic segments with high-end products. The company's forward-looking布局 has resulted in a diverse and differentiated portfolio, leading the industry in both the number of products and coverage areas. It currently boasts over 40 high-end products in the "non-invasive + minimally invasive" aesthetics field, including more than 20 marketed products domestically and internationally, and over 10 global innovative products in development. This portfolio covers mainstream non-surgical areas such as dermal fillers, facial cleansing, thread lifting, skin management, body contouring, hair removal, and intimate wellness, forming a comprehensive product cluster that enhances its international influence.
In injectables, Huadong Medicine has achieved full coverage across three major categories: regenerative agents, hyaluronic acid, and botulinum toxin. Key products include Ellansé®, MaiLi hyaluronic acid, Lanluma®, and the newly approved Ruituoxin® botulinum toxin, all launched in China. Each category features at least two differentiated pipelines, providing solid support for meeting diverse market needs and building competitive barriers. Ellansé® is a core product, renowned for its triple effect of "instant filling + long-lasting maintenance + natural metabolism," earning it the nickname "Youth Shot." The S-type is already marketed in China as the first imported PCL-based dermal filler certified as a Class III medical device, and its US clinical trial has completed patient enrollment. The M-type's registration application was accepted by the NMPA in January 2025 and is nearing approval. Huadong Medicine is advancing the domestic registration of the MaiLi series, with clinical trials conducted for MaiLi Precise and MaiLi Extreme. MaiLi Extreme, the variant with the highest hyaluronic acid concentration and strongest volumizing capacity, commenced commercial sales in May 2025. The registration application for MaiLi Precise, the variant with the lowest sodium hyaluronate concentration, was accepted by the NMPA in October 2025. Additionally, clinical trials for Lanluma®, a poly-L-lactic acid collagen stimulator, are progressing vigorously. Lanluma® is reportedly the first global regenerative product approved for buttock and thigh augmentation. It comes in V-type for smaller areas like the face and upper arms, and X-type for larger areas like the buttocks, with its main component PLLA often referred to as "Sculptra" in China.
In the energy-based device sector, the company also achieves comprehensive high-end market coverage. Domestically approved products include the cryotherapy-based whitening system Glacial Spa and the radiofrequency anti-aging systems. The registration application for the versatile aesthetic system V30 was accepted in 2025; its future launch will further consolidate Huadong Medicine's leading position in non-surgical aesthetic devices. Internationally, the company is advancing clinical work for its injectable filler pipeline to accelerate the globalization of its high-end aesthetics business. Patient enrollment is complete for the domestic clinical trial of KIO021, a novel dermal filler with a patented composition. KIO021 shares the same composition as KIO015 but in a different specification; KIO015 is currently under technical review for EU MDR-CE certification.
The successful approval of Ruituoxin® marks a significant milestone for Huadong Medicine in medical aesthetics and underscores its commitment to meeting the diverse, high-quality treatment needs of Chinese patients. Moving forward, the company will continue to leverage its global R&D perspective and deep local commercialization capabilities to translate cutting-edge technology into exceptional products, creating long-term value and opening a new chapter of growth amidst the upgrading wave of the medical aesthetics industry in China and globally.
Comments